subscribeSubscribe
Novartis` Arzerra (ofatumumab) Receives Suppl Approval in the U.S.

Novartis` Arzerra (ofatumumab) Receives Suppl Approval in the U.S.

FDA
12 Apr 2024
Share Share
Novartis` Kesimpta (ofatumumab) Receives Suppl Approval in the U.S.

Novartis` Kesimpta (ofatumumab) Receives Suppl Approval in the U.S.

FDA
12 Apr 2024
Share Share
Novartis presents new five-year data disability outcomes and safety of Kesimpta

Novartis presents new five-year data disability outcomes and safety of Kesimpta
GLOBENEWSWIRE
20 Apr 2023
Share Share
Novartis presents new 5-year data on disability outcomes and safety of Kesimpta

Novartis presents new 5-year data on disability outcomes and safety of Kesimpta
PR NEWSWIRE
19 Apr 2023
Share Share
Novartis` Kesimpta Receives Approval in Europe

Novartis` Kesimpta Receives Approval in Europe
EMA
08 Dec 2022
Share Share
Novaris`s Biologic Arzerra (Ofatumumab) Receives Approval in the U.S.

Novaris`s Biologic Arzerra (Ofatumumab) Receives Approval in the U.S.
FDA
02 Sep 2022
Share Share
Kesimpta surges as Kisqali starts to ramp at Novartis

Kesimpta surges as Kisqali starts to ramp at Novartis
Angus Liu FIERCEPHARMA
19 Jul 2022
Share Share
FDA Warns of Increased Mortality Risk With Duvelisib

FDA Warns of Increased Mortality Risk With Duvelisib
Mike Bassett MEDPAGETODAY
01 Jul 2022
Share Share
Continuous treatment with Kesimpta sees RMS patients achieving NEDA-3

Continuous treatment with Kesimpta sees RMS patients achieving NEDA-3
Sarah Wills EUROPEANPHARMACEUTICALREVIEW
30 Jun 2022
Share Share
New peer-reviewed research shows no increased risk of serious COVID-19 infections in Kesimpta® (ofatumumab)-treated adults with multiple sclerosis

New peer-reviewed research shows no increased risk of serious COVID-19 infections in Kesimpta® (ofatumumab)-treated adults with multiple sclerosis
PRESS RELEASE
18 Mar 2022
Share Share